| 1 |
2019 |
A biomarker for tegumentary and visceral leishmaniasis based on a recombinant Leishmania hypothetical protein. |
VL |
| 2 |
2019 |
A randomized, open-label clinical trial comparing the long-term effects of miltefosine and meglumine antimoniate for mucosal leishmaniasis. |
CI |
| 3 |
2019 |
Comparative study on liposomal amphotericin B and other therapies in the treatment of mucosal leishmaniasis: A 15-year retrospective cohort study. |
ABLC, AEs, CI, d-AMB, L-AmB, OR |
| 4 |
2019 |
Cost-effectiveness analysis of Mucosal Leishmaniasis diagnosis with PCR-based vs parasitological tests in Colombia. |
DALY, DES, GDPpc, ICERs, IFA, MST, WTP |
| 5 |
2019 |
Gene expression profile of cytokines produced in biopsies from patients with American cutaneous leishmaniasis. |
ACL, CL, FFPE, RQ |
| 6 |
2019 |
In Situ Cellular Response Underlying Successful Treatment of Mucosal Leishmaniasis with a Combination of Pentavalent Antimonial and Pentoxifylline. |
PTX |
| 7 |
2019 |
Mucosal Leishmaniasis in Travelers with Leishmania braziliensis Complex Returning to Israel. |
CL |
| 8 |
2019 |
Phonotherapeutic Intervention in Patients With Mucosal Leishmaniasis Sequelae. |
CL |
| 9 |
2019 |
Successful treatment by adding thalidomide to meglumine antimoniate in a case of refractory anthroponotic mucocutaneous leishmaniasis. |
--- |
| 10 |
2018 |
Case Report: Mucosal Leishmaniasis Presenting with Nasal Septum Perforation after Almost Thirty Years. |
--- |
| 11 |
2018 |
Cellular Markers of Active Disease and Cure in Different Forms of Leishmania infantum-Induced Disease. |
CL, LLL, PBMC, SLA, SLA-CPA, VL |
| 12 |
2018 |
Diagnostic application of recombinant Leishmania proteins and evaluation of their in vitro immunogenicity after stimulation of immune cells collected from tegumentary leishmaniasis patients and healthy individuals. |
--- |
| 13 |
2018 |
Mucosal leishmaniasis: the experience of a Brazilian referral center. |
AmB |
| 14 |
2018 |
Promastigote parasites cultured from the lesions of patients with mucosal leishmaniasis are more resistant to oxidative stress than promastigotes from a cutaneous lesion. |
LCL, NO, ROS, TSA |
| 15 |
2018 |
Safety and efficacy of miltefosine monotherapy and pentoxifylline associated with pentavalent antimony in treating mucosal leishmaniasis. |
--- |
| 16 |
2017 |
AIM2 inflammasome is associated with disease severity in tegumentary leishmaniasis caused by Leishmania (V.) braziliensis. |
CL, TL |
| 17 |
2017 |
Annexin A1 Is Involved in the Resolution of Inflammatory Responses during Leishmania braziliensis Infection. |
ANXA1, LCL, WT |
| 18 |
2017 |
Dynamics of American tegumentary leishmaniasis in a highly endemic region for Leishmania (Viannia) braziliensis infection in northeast Brazil. |
ATL, CL, DL |
| 19 |
2017 |
Field Validation of SYBR Green- and TaqMan-Based Real-Time PCR Using Biopsy and Swab Samples To Diagnose American Tegumentary Leishmaniasis in an Area Where Leishmania (Viannia) braziliensis Is Endemic. |
ATL, CI, CL |
| 20 |
2017 |
Mucosal leishmaniasis: A Retrospective Study of 327 Cases from an Endemic Area of Leishmania (Viannia) braziliensis. |
ATL |
| 21 |
2016 |
Intestinal helminth coinfection is associated with mucosal lesions and poor response to therapy in American tegumentary leishmaniasis. |
ATL, PSE |
| 22 |
2016 |
Leishmania (Viannia) braziliensis amastigotes from patients with mucosal leishmaniasis have increased ability to disseminate and are controlled by nitric oxide at the early stage of murine infection. |
iNOS, LCL |
| 23 |
2016 |
Otolaryngological manifestations of leishmaniosis. |
CL, NTD, VL |
| 24 |
2016 |
Quantitative Kinetoplast DNA Assessment During Treatment of Mucosal Leishmaniasis as a Potential Biomarker of Outcome: A Pilot Study. |
kDNA-qPCR, PL |
| 25 |
2015 |
Correlation between presence of Leishmania RNA virus 1 and clinical characteristics of nasal mucosal leishmaniosis. |
LRV1, PCR |
| 26 |
2015 |
Efficacy and Safety of Liposomal Amphotericin B for the Treatment of Mucosal Leishmaniasis from the New World: A Retrospective Study. |
--- |
| 27 |
2015 |
Further Evidence of an Association between the Presence of Leishmania RNA Virus 1 and the Mucosal Manifestations in Tegumentary Leishmaniasis Patients. |
CL, DCL, DL, TL |
| 28 |
2015 |
Mucosal leishmaniasis of the lip: an emerging clinical form in Tunisia. |
MA, PCR |
| 29 |
2015 |
Mucosal leishmaniasis with primary oral involvement: a case series and a review of the literature. |
--- |
| 30 |
2015 |
Wound healing genes and susceptibility to cutaneous leishmaniasis in Brazil: role of COL1A1. |
Col1a1, FBAT, Mmp1, SNPs |
| 31 |
2014 |
Antigen-triggered interferon-gamma and interleukin-10 pattern in cured mucosal leishmaniasis patients is shaped during the active phase of disease. |
Con A, ELISPOT, IFN, IL, Lb-Ag, MST, PBMC, Tg-Ag |
| 32 |
2014 |
Facial structure alterations and abnormalities of the paranasal sinuses on multidetector computed tomography scans of patients with treated mucosal leishmaniasis. |
MDCT |
| 33 |
2014 |
LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014. |
CL |
| 34 |
2014 |
Liposomal formulation of amphotericin B for the treatment of mucosal leishmaniasis in HIV-negative patients. |
LAB |
| 35 |
2014 |
Reactivation of mucosal and cutaneous leishmaniasis in a renal transplanted patient. |
--- |
| 36 |
2014 |
The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of human tegumentary leishmaniasis. |
CL |
| 37 |
2014 |
Voice disorders in mucosal leishmaniasis. |
--- |
| 38 |
2013 |
Candidate gene case-control and functional study shows macrophage inhibitory factor (MIF) polymorphism is associated with cutaneous leishmaniasis. |
ATL, CL, MIF, SNPs |
| 39 |
2013 |
Cutaneous leishmaniasis in Switzerland: first experience with species-specific treatment. |
CL |
| 40 |
2013 |
Immunologic response and memory T cells in subjects cured of tegumentary leishmaniasis. |
CL, LST, SLA |
| 41 |
2013 |
Influence of the nutritional status in the clinical and therapeutical evolution in adults and elderly with American Tegumentary Leishmaniasis. |
ATL, BMI |
| 42 |
2013 |
Molecular, cytological, and immunocytochemical study and kDNA sequencing of laryngeal Leishmania infantum infection. |
--- |
| 43 |
2013 |
Mucosal leishmaniasis: an underestimated presentation of a neglected disease. |
--- |
| 44 |
2013 |
Real-time PCR assay for detection and quantification of Leishmania (Viannia) organisms in skin and mucosal lesions: exploratory study of parasite load and clinical parameters. |
CL, G6PD, kDNA, qPCR |
| 45 |
2012 |
A proposed new clinical staging system for patients with mucosal leishmaniasis. |
--- |
| 46 |
2012 |
Association between an emerging disseminated form of leishmaniasis and Leishmania (Viannia) braziliensis strain polymorphisms. |
ATL, CL, DL, SNPs |
| 47 |
2012 |
Comparative study of the in situ immune response in oral and nasal mucosal leishmaniasis. |
NOS2 |
| 48 |
2012 |
Cutaneous leishmaniasis in Royal Marines from Oruzgan, Afghanistan. |
CL, VL |
| 49 |
2012 |
Genetic polymorphism in Leishmania (Viannia) braziliensis detected in mucosal leishmaniasis of HIV-infected and non-HIV-infected patients. |
LSSP-PCR, PCR |
| 50 |
2012 |
Improvements in obtaining New World Leishmania sp from mucosal lesions: notes on isolating and stocking parasites. |
CL |
| 51 |
2012 |
Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis. |
CL |
| 52 |
2012 |
Macrophages participate in host protection and the disease pathology associated with Leishmania braziliensis infection. |
CL, HS, NO, SC |
| 53 |
2012 |
Mixed mucosal leishmaniasis infection caused by Leishmania tropica and Leishmania major. |
--- |
| 54 |
2012 |
Molecular diagnosis and species identification of mucosal leishmaniasis in Iran and correlation with cytological findings. |
--- |
| 55 |
2012 |
Transcriptome patterns from primary cutaneous Leishmania braziliensis infections associate with eventual development of mucosal disease in humans. |
LCL |
| 56 |
2011 |
American tegumentary leishmaniasis and HIV-AIDS association in a tertiary care center in the Brazilian Amazon. |
AIDS, ATL, HIV |
| 57 |
2011 |
Clinical, histopathologic, and cytologic diagnosis of mucosal leishmaniasis and literature review. |
--- |
| 58 |
2011 |
First report on Ambisome-associated allergic reaction in two Sudanese leishmaniasis patients. |
PKDL |
| 59 |
2011 |
FLI1 polymorphism affects susceptibility to cutaneous leishmaniasis in Brazil. |
CL, OR |
| 60 |
2011 |
MMP-9 activity is induced by Leishmania braziliensis infection and correlates with mucosal leishmaniasis. |
LCL, MMP-9 |
| 61 |
2011 |
Mucosal Leishmaniasis caused by Leishmania (Viannia) braziliensis and Leishmania (Viannia) guyanensis in the Brazilian Amazon. |
PCR |
| 62 |
2011 |
Non-invasive cytology brush PCR diagnostic testing in mucosal leishmaniasis: superior performance to conventional biopsy with histopathology. |
LST |
| 63 |
2010 |
A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis. |
--- |
| 64 |
2010 |
Human mucosal leishmaniasis: neutrophils infiltrate areas of tissue damage that express high levels of Th17-related cytokines. |
CCR6 |
| 65 |
2010 |
Mucosal leishmaniasis and abnormalities on computed tomographic scans of paranasal sinuses. |
CT |
| 66 |
2010 |
The -2518bp promoter polymorphism at CCL2/MCP1 influences susceptibility to mucosal but not localized cutaneous leishmaniasis in Brazil. |
CL, FBAT, MCP-1, NC |
| 67 |
2009 |
Mucosal leishmaniasis in a Sudanese patient. |
VL |
| 68 |
2008 |
Histopathology of mast cells and cytokines during healing of human mucosal leishmaniasis. |
MCs |
| 69 |
2008 |
Local immunological factors associated with recurrence of mucosal leishmaniasis. |
--- |
| 70 |
2008 |
Mucosal leishmaniasis . Current scenario and prospects for treatment. |
--- |
| 71 |
2007 |
Can interferon-gamma and interleukin-10 balance be associated with severity of human Leishmania (Viannia) braziliensis infection? |
ASY, CCL, CL, CML, ELISA, IFN, IL, PBMC, SH |
| 72 |
2007 |
Differential immune regulation of activated T cells between cutaneous and mucosal leishmaniasis as a model for pathogenesis. |
PBMC |
| 73 |
2007 |
Treatment of mucosal leishmaniasis in Latin America: systematic review. |
--- |
| 74 |
2006 |
Concomitant early mucosal and cutaneous leishmaniasis in Brazil. |
--- |
| 75 |
2006 |
Generic sodium stibogluconate is as safe and effective as branded meglumine antimoniate, for the treatment of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia. |
CL, SSG |
| 76 |
2006 |
IL6 -174 G/C promoter polymorphism influences susceptibility to mucosal but not localized cutaneous leishmaniasis in Brazil. |
CI, CL, FBAT, IL, OR, Th |
| 77 |
2006 |
Immunotherapy for drug-refractory mucosal leishmaniasis. |
CC |
| 78 |
2006 |
Mucosal leishmaniasis patients display an activated inflammatory T-cell phenotype associated with a nonbalanced monocyte population. |
CL, SLA |
| 79 |
2005 |
Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis. |
CL, IL-10 |
| 80 |
2005 |
Effect of LACK and KMP11 on IFN-gamma production by peripheral blood mononuclear cells from cutaneous and mucosal leishmaniasis patients. |
CL, IFN-gamma, IL-10, KMP11, LACK, PBMC, SLA |
| 81 |
2005 |
Familial aggregation of mucosal leishmaniasis in northeast Brazil. |
CL, DTH |
| 82 |
2005 |
Polymerase chain reaction (PCR) is highly sensitive for diagnosis of mucosal leishmaniasis. |
MST, PCR |
| 83 |
2004 |
New world mucosal and cutaneous leishmaniasis: an emerging health problem among British travellers. |
CL |
| 84 |
2003 |
Mucosal leishmaniasis: in situ characterization of the host inflammatory response, before and after treatment. |
--- |
| 85 |
2003 |
Short report: persistence of tumor necrosis factor-alpha in situ after lesion healing in mucosal leishmaniasis. |
TNF-alpha |
| 86 |
2003 |
[On the origin and spread of cutaneous and mucosal leishmaniasis, based on pre- and post- colombian historical source]. |
--- |
| 87 |
2002 |
Parasitological and immunological follow-up of American tegumentary leishmaniasis patients. |
CL, DNA, IFN-gamma, PCR |
| 88 |
2002 |
T-cell-mediated immune responses in patients with cutaneous or mucosal leishmaniasis: long-term evaluation after therapy. |
CL, IL-5 |
| 89 |
2000 |
Mucosal leishmaniasis: quantitative nasal cytology as a marker of disease activity and indicator of healing. |
CL, QNCs |
| 90 |
1998 |
An evaluation of clinical, serologic, anatomopathologic and immunohistochemical findings for fifteen patients with mucosal leishmaniasis before and after treatment. |
IISR |
| 91 |
1997 |
Parasite-driven in vitro human lymphocyte cytotoxicity against autologous infected macrophages from mucosal leishmaniasis. |
CL |
| 92 |
1991 |
Studies on the leishmaniases in the Sudan. 3. Clinical and parasitological studies on visceral and mucosal leishmaniasis. |
VL |
| 93 |
1985 |
Cell mediated immunity in American cutaneous and mucosal leishmaniasis. |
CL |
A Search Service for Abbreviation / Long Form
